Chiral effects in adrenocorticolytic action of o,p′-DDD (mitotane) in human adrenal cells

References

• Ahlman H, Khorram-Manesh A, Jansson S, Wangberg B, Nilsson O, Jacobsson CE, Lindstedt S. (2001). Cytotoxic treatment of adrenocortical carcinoma. World J Surg 25(7):927–33.
   Google Scholar
• Allolio B, Fassnacht M. (2006). Clinical Review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91(6):2027–37.
   Google Scholar
• Asp V, Lindström V, Olsson JA, Bergström U, Brandt I. (2009). Cytotoxicity and decreased corticosterone production in adrenocortical Y-1 cells by 3-methylsulfonyl-DDE and structurally related molecules. Archiv Toxicol 83(4):389–96.
   Google Scholar
• Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G, Schlumberger M. (2001). Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p′-DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92(6): 1385–92.
   Google Scholar
• Bergenstal D, Hertz R, Lipsett M, Moy R. (1960). Chemotherapy of adrenocortical cancer with o,p′-DDD. Ann Intern Med 53:672–82.
   Web of Science ®Google Scholar
• Cai W, Benitez R, Counsell RE, Djanegara T, Schteingart DE, Sinsheimer JE, Wotring LL. (1995a). Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p′-DDD] and its p,p′- and m,p′-isomers. Biochem Pharmacol 49(10):1483–9.
   Google Scholar
• Cai W, Djanegara T, Sinsheimer J, Wotring L, Counsell E, Schteingart D. (1995b). Metabolic activation and binding of mitotane in adrenal cortex homogenates. J Pharmaceut Sci 84(2):134–8.
   Google Scholar
• Cantillana T, Eriksson L. (2009). (2S)-1,1-dichloro-2-(2-chlorophenyl)-2-(4-chlorophenyl)ethane. Acta Crystallographica E65:o297.
   Google Scholar
• Cantillana T, Lindstrom V, Eriksson L, Brandt I, Bergman A. (2009). Interindividual differences in o,p′-DDD enantiomer kinetics examined in Gottingen minipigs. Chemosphere 76(2):167–72.
   Google Scholar
• Eriksson T, Björkman S, Höglund P. (2001). Clinical pharmacology of thalidomide. European J Clin Pharmacol 57(5):365–76.
   Google Scholar
• Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, Krans HM. (1994). Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69(5):947–51.
   Google Scholar
• Hahner S, Fassnacht M. (2005). Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 6(4):386–94.
   Google Scholar
• Hart MM, Reagan RL, Adamson RH. (1973). The effect of isomers of DDD on the ACTH-induced steroid output, histology and ultrastructure of the dog adrenal cortex. Toxicol Appl Pharmacol 24(1):101–13.
   Google Scholar
• Hart MM, Straw JA. (1971). Studies on the site of action of o,p′-DDD in the dog adrenal cortex. 1. Inhibition of ACTH-mediated pregnenolone synthesis. Steroids 17(1–5):559–74.
   Google Scholar
• Hart MM, Swackhamer ES, Straw JA. (1971). Studies on the site of action of o,p′-DDD in the dog adrenal cortex. II. TPNH- and corticosteroid precursor-stimulation of o,p′-DDD inhibited steroidogenesis. Steroids 17(1–5):575–86.
   Google Scholar
• Hoekstra PF, Burnison BK, Neheli T, Muir DC. (2001). Enantiomer-specific activity of o,p′-DDT with the human estrogen receptor. Toxicol Lett 125(1–3):75–81.
   Google Scholar
• Huang H, Fojo T. (2008). Adjuvant mitotane for adrenocortical cancer — a recurring controversy. J Clin Endocrinol Metab 93(10):3730–2.
   Google Scholar
• Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C. (2001). Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25(7):891–7.
   Google Scholar
• Lindholm A, Klasson-Wehler E, Wehler T, Bergman Å. (1987). Synthesis of 14C-labelled DDD isomers of high specific activity. J Labelled Comp Radiopharm 24:1011–9.
   Google Scholar
• Lund BO, Ghantous H, Bergman å, Brandt I. (1989). Covalent binding of four DDD isomers in the mouse lung: lack of structure specificity. Pharmacol Toxicol 65(4):282–6.
   Google Scholar
• Lund BO, Klasson-Wehler E, Brandt I. (1986). o,p′-DDD in the mouse lung: selective uptake, covalent binding and effect on drug metabolism. Chemico-Biol Interact 60(2):129–41.
   Google Scholar
• Martz F, Straw JA. (1977). The in vitro metabolism of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p′-DDD) by dog adrenal mitochondria and metabolite covalent binding to mitochondrial macromolecules: a possible mechanism for the adrenocorticolytic effect. Drug Metab Dispos 5(5):482–6.
   Google Scholar
• Martz F, Straw JA. (1980). Metabolism and covalent binding of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p′-DDD). Correlation between adrenocorticolytic activity and metabolic activation by adrenocortical mitochondria. Drug Metab Dispos 8(3):127–30.
   Google Scholar
• Newell-Price J, Bertagna X, Grossman AB, Nieman LK. (2006). Cushing’s syndrome. Lancet 367(9522):1605–17.
   Google Scholar
• Shen H, Virtanen HE, Main KM, Kaleva M, Andersson AM, Skakkebaek NE, Toppari J, Schramm KW. (2006). Enantiomeric ratios as an indicator of exposure processes for persistent pollutants in human placentas. Chemosphere 62(3):390–5.
   Google Scholar
• Tada H, Shiho O, Kuroshima K, Koyama M, Tsukamoto K. (1986). An improved colorimetric assay for interleukin 2. J Immunol Methods 93(2):157–65.
   Google Scholar
• Tauchmanova L, Colao A, Marzano LA, Sparano L, Camera L, Rossi A, Palmieri G, Marzano E, Salvatore M, Pettinato G, Rossi R, (2004). Andrenocortical carcinomas: twelve-year prospective experience. World J Surg 28(9):896–903.
   Google Scholar
• Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker A-C, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A (2007). Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. N Engl J Med 356(23):2372–80.
   Google Scholar
• Terzolo M, Berruti A. (2008). Adjunctive treatment of adreno-cortical carcinoma. Curr Opin Endocrinol Diabet Obes 15(3):221–6.
   Google Scholar
• van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D. (1984). The treatment of adrenocortical carcinoma with o,p′-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20(1):47–53.
   Google Scholar